705TiP Phase II trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti-TIM-3) as first-line treatment in patients with PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 33; p. S865
Main Authors	Le Tourneau, C., Licitra, L.F., Bourayou, N., Schaub, R., Bartenstein, M., Wei, W., Cohen, E.E.W.
Format	Journal Article
Language	English
Published	01.09.2022
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.07.829